Highly enantioselective syntheses of α-hydroxyacids using N-benzyl-4,4,7α-trimethyl--octahydro-1, 3-benzoxazine as a chiral adjuvant
作者:Xu-Chang He、Ernest L. Eliel
DOI:10.1016/s0040-4020(01)87677-8
日期:1987.1
Addition of Grignard and organolithium reagents to as well as hydride reduction of 2α-benzoyl-N-benzyl-4,4,7α-trimethyl--octahydro-1 ,3-benzoxazine (2, Y = C6H5CO) and addition of phenylmagnesium bromide to the corresponding 2-acetyl analog (11) proceed in highly diastereoselective fashion to produce virtually exclusively the diastereomer predicted on the basis of Cram's chelate rule if chelation involves
添加格氏试剂和有机锂试剂,以及将2α-苯甲酰基-N-苄基-4,4,7α-三甲基-八氢-1,3-苯并恶嗪(2,Y = C 6 H 5 CO)氢化还原并添加如果螯合涉及环氧原子,则将苯基溴化镁与相应的2-乙酰基类似物(11)进行高非对映选择性的方式,实际上仅产生根据克拉姆螯合规则预测的非对映异构体。加合物的轻度酸水解,然后进行选择性氧化,可生成高对映体纯的对羟基酸,并且可以干净地回收手性佐剂。
Anticholinergic drugs
申请人:FMC Corporation
公开号:US04465834A1
公开(公告)日:1984-08-14
A class of anticholinergic drugs having the formula ##STR1## in which R.sup.1 is a carbocyclic or branched aliphatic group of 3 to 8 carbon atoms, R.sup.2 is a branched or linear aliphatic group containing 3 to 10 carbon atoms with 1 to 2 olefinic or acetylenic bonds and R.sup.3 is an alkyl or cyclic group of 4 to 12 carbon atoms containing a tertiary amino nitrogen, are described.
Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme
申请人:Liu Gang
公开号:US20080293713A1
公开(公告)日:2008-11-27
The present invention relates to compounds of formula (I):
wherein R
1
, R
2
, and R
3
, are defined herein. Pharmaceutical compositions and methods for treating DGAT-
1
related diseases or conditions are also disclosed.
INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME
申请人:Liu Gang
公开号:US20120041003A1
公开(公告)日:2012-02-16
The present invention relates to compounds of formula (I):
wherein R
1
, R
2
, and R
3
, are defined herein. Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.
Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
申请人:Abbott Laboratories
公开号:EP2500347A1
公开(公告)日:2012-09-19
The present invention relates to compounds of formula (I): wherein R1, R2, and R3, are defined herein. Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.